Add‐on cannabidiol in patients with Dravet syndrome: Results of a long‐term open‐label extension trial

Objective Add‐on cannabidiol (CBD) reduced seizures associated with Dravet syndrome (DS) in two randomized, double‐blind, placebo‐controlled trials: GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or GWPCARE2, were enrolled in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Epilepsia (Copenhagen) 2021-10, Vol.62 (10), p.2505-2517
Hauptverfasser:	Scheffer, Ingrid E., Halford, Jonathan J., Miller, Ian, Nabbout, Rima, Sanchez‐Carpintero, Rocio, Shiloh‐Malawsky, Yael, Wong, Matthew, Zolnowska, Marta, Checketts, Daniel, Dunayevich, Eduardo, Devinsky, Orrin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Anticonvulsants - adverse effects antiseizure medication Appetite loss Cannabidiol Cannabidiol - adverse effects cannabinoid Cannabinoids childhood onset epilepsy Clinical trials convulsive seizures Diarrhea Double-Blind Method Double-blind studies Dravet syndrome Epilepsies, Myoclonic - drug therapy Epileptic Syndromes Fever Humans Patients Placebos Seizures Seizures - drug therapy Transaminase Treatment Outcome Valproic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!